2021 PrEP Clinical Practice Guideline

Comprehensive information for the use of antiretroviral preexposure prophylaxis (PrEP) to prevent acquiring HIV infection.

Updates for 2021 include:

  • A recommendation to inform all sexually active adults and adolescents about PrEP
  • PrEP with intramuscular cabotegravir (CAB) injections (conditional on FDA approval) is recommended for HIV prevention in adults reporting sexual behaviors that place them at substantial ongoing risk of HIV exposure and acquisition.

Also view the updated PrEP Providers Supplement for 2021.

CDC logo